Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | FABP7 | O15540 | 1/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119285 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL3728954 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL29401217 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL29401300 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL29775608 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL25178646 | 0.90 | MDM2 (0.51) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL30802574 | 0.90 | MDM2 (0.51) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL25178647 | 0.90 | MDM2 (0.51) | MDM4TP53CASP3FABP7FABP5 | |
| SCHEMBL30951908 | 0.89 | MDM4 (0.51) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL30951920 | 0.89 | MDM4 (0.51) | MDM4TP53CASP3SLC17A5MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116706230-B | High-voltage electrolyte for lithium battery | 浙江大学 | 2024-02-02 | — | — | CN | claimed |
| CN-116706230-A | High-voltage electrolyte for lithium battery | 浙江大学 | 2023-09-05 | — | — | CN | claimed |
| CN-113214567-A | Corrosion-resistant plastic lower cover and manufacturing process thereof | 苏州工业园区宏图精密科技有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-111019313-A | Corrosion-resistant engineering plastic and preparation method thereof | 江门市江海区新雄利塑料科技有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117279933-A | Cyclic compounds having selective KRAS inhibition relative to HRAS and NRAS | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| CN-113214567-A | Corrosion-resistant plastic lower cover and manufacturing process thereof | 苏州工业园区宏图精密科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-111019313-A | Corrosion-resistant engineering plastic and preparation method thereof | 江门市江海区新雄利塑料科技有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-2970390-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022321-A2 | SUBSTITUTED INDOLES AND USE THEREOF | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20060172938-A1 | Peptide inhibitors against seprase | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2006-08-03 | — | — | US | disclosed |
| WO-2006042282-A2 | PEPTIDE INHIBITORS AGAINST SEPRASE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060062797-A1 | Novel materials and methods for the treatment of Alzheimer's disease patients | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AT STONY BROOK | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043101-A1 | Substituted indoles and methods of their use | INMT, AANAT, IDO2 | MDM4 1192/4885TP53 401/4885CASP3 2025/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885CASP3 3906/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | MDM4 1166/4885TP53 1635/4885CASP3 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.